Efficacy and safety of fruquintinib in treatment of advanced malignant tumors based on real-world

Qu Jun-chen; Lu Yin-qiu; Yin Qiu-yi; Tang Jian; Gu Yu-lan; Zhou Chen-xia

doi:10.3969/j.issn.1672-8157.2025.02.033

Abstract：Objective To observe the efficacy and safety of fruquintinib in the second-and third-line treatment of advanced lung cancer and colorectal cancer in the real world and analyze the risk factors for adverse reaction(ADR)for clinical monitoring and prevention.Methods Patients with colorectal cancer and lung cancer who received treatment with fruquintinib for the first time in Changshu Second People's Hospital from January 2021 to June 2023 were selected as the study subjects.The observational study was conducted using a cross-sectional approach,with specific components including collection of case data,evaluation of clinical efficacy,documentation of adverse reactions,and follow-up on disease outcomes.The response rate,time to remission and incidence of adverse reactions of fruquintinib were statistically analyzed.Binary logistic regression was used to analyze the clinical risk factors for the occurrence of adverse reactions.Results Forty-three patients,including 26 patients with colorectal cancer and 17 patients with lung cancer,were treated with fruquintinib monotherapy or in combination with chemotherapy,targeted therapy,or immunotherapy,respectively.Objective response rate(ORR)and disease control rate(DCR)were 23.1%and 69.2%for colorectal cancer and 5.9%and 64.7%for lung cancer at the eighth week.Median progression-free survival(PFS)was 4.6 months(maximum PFS 15.4 months)for colorectal cancer and 5.1 months(maximum PFS 7.3 months)for lung cancer,96%,85%,69%and 42%for colorectal cancer(36.6 months follow-up and still alive)and 100%,88%,53%and 18%for lung cancer(14.1 months for maxi-mum follow-up and still alive).The incidence of adverse reactions was 90.7%,and 32.6%for grade 3 and above.The main ADRs included hand and foot skin reactions(53.5%),abdominal distension,abdominal pain/abdominal discomfort(39.5%),hypertension(37.2%),fatigue(34.9%),proteinuria(30.2%),and abnormal liver function(23.3%).Analysis of risk factors for adverse reactions indicated that fatigue was significantly associated with advanced age(≥65 years old)and female sex(P<0.05).In addition,pro-teinuria was significantly associated with overweight(P<0.05),and the risk of proteinuria in colorectal cancer patients was signifi-cantly higher than that in lung cancer patients(P<0.05).Conclusion The efficacy of fruquintinib in the second-and third-line treatment of advanced colorectal cancer and lung cancer is clear.Furthermore,elderly and overweight patients are high-risk popula-tions for adverse reactions that require special attention.